Abdo, W.F.; van de Warrenburg, B.P.C.; Burn, D.J.; Quinn, N.P.; Bloem, B.R. The clinical approach to movement disorders. Nat. Rev. Neurol., 2010, 6(1), 29-37.
[http://dx.doi.org/10.1038/nrneurol.2009.196]

Jankovic, J. Treatment of hyperkinetic movement disorders. Lancet Neurol., 2009, 8(9), 844-856.
[http://dx.doi.org/10.1016/S1474-4422(09)70183-8]

André, V.M.; Cepeda, C.; Levine, M.S. Dopamine and glutamate in huntington’s disease: A balancing act. CNS Neurosci. Ther., 2010, 16(3), 163-178.
[http://dx.doi.org/10.1111/j.1755-5949.2010.00134.x]

Frank, S.; Testa, C.M.; Stamler, D.; Kayson, E.; Davis, C.; Edmondson, M.C.; Kinel, S.; Leavitt, B.; Oakes, D.; O’Neill, C.; Vaughan, C.; Goldstein, J.; Herzog, M.; Snively, V.; Whaley, J.; Wong, C.; Suter, G.; Jankovic, J.; Jimenez-Shahed, J.; Hunter, C.; Claassen, D.O.; Roman, O.C.; Sung, V.; Smith, J.; Janicki, S.; Clouse, R.; Saint-Hilaire, M.; Hohler, A.; Turpin, D.; James, R.C.; Rodriguez, R.; Rizer, K.; Anderson, K.E.; Heller, H.; Carlson, A.; Criswell, S.; Racette, B.A.; Revilla, F.J.; Nucifora, F., Jr; Margolis, R.L.; Ong, M.J.; Mendis, T.; Mendis, N.; Singer, C.; Quesada, M.; Paulsen, J.S.; Brashers-Krug, T.; Miller, A.; Kerr, J.; Dubinsky, R.M.; Gray, C.; Factor, S.A.; Sperin, E.; Molho, E.; Eglow, M.; Evans, S.; Kumar, R.; Reeves, C.; Samii, A.; Chouinard, S.; Beland, M.; Scott, B.L.; Hickey, P.T.; Esmail, S.; Fung, W.L.A.; Gibbons, C.; Qi, L.; Colcher, A.; Hackmyer, C.; McGarry, A.; Klos, K.; Gudesblatt, M.; Fafard, L.; Graffitti, L.; Schneider, D.P.; Dhall, R.; Wojcieszek, J.M.; LaFaver, K.; Duker, A.; Neefus, E.; Wilson-Perez, H.; Shprecher, D.; Wall, P.; Blindauer, K.A.; Wheeler, L.; Boyd, J.T.; Houston, E.; Farbman, E.S.; Agarwal, P.; Eberly, S.W.; Watts, A.; Tariot, P.N.; Feigin, A.; Evans, S.; Beck, C.; Orme, C.; Edicola, J.; Christopher, E. Effect of deutetrabenazine on chorea among patients with huntington disease. JAMA, 2016, 316(1), 40-50.
[http://dx.doi.org/10.1001/jama.2016.8655]

Bashir, H.; Jankovic, J. Treatment options for chorea. Expert Rev. Neurother., 2018, 18(1), 51-63.
[http://dx.doi.org/10.1080/14737175.2018.1403899]

Coppen, E.M.; Roos, R.A.C. Current pharmacological approaches to reduce chorea in huntington’s disease. Drugs, 2017, 77(1), 29-46.
[http://dx.doi.org/10.1007/s40265-016-0670-4]

Crosby, N.J.; Deane, K.; Clarke, C.E. Amantadine for dyskinesia in Parkinson’s disease. Cochrane Database of Systematic Reviews; John Wiley and Sons Ltd, 2010.

Reilmann, R. Pharmacological treatment of chorea in Huntington’s disease-good clinical practice versus evidence-based guideline. Mov. Disord., 2013, 28(8), 1030-1033.
[http://dx.doi.org/10.1002/mds.25500]

Smith, K.M.; Spindler, M.A. Uncommon applications of deep brain stimulation in hyperkinetic movement disorders. Tremor Other Hyperkinet. Mov. , 2015, 5, 278.
[http://dx.doi.org/10.5334/tohm.265]

Posturna, R.B.; Lang, A.E. Hemiballism: Revisiting a classic disorder. Lancet Neurol., 2003, 2(11), 661-668.
[http://dx.doi.org/10.1016/S1474-4422(03)00554-4]

Whittier, J.R. Ballism and the subthalamic nucleus (Nucleus Hypothalamicus; Corpus Luysi). Arch. Neurol. Psychiatry, 1947, 58(6), 672-692.
[http://dx.doi.org/10.1001/archneurpsyc.1947.02300350022002]

Mehanna, R.; Jankovic, J. Movement disorders in cerebrovascular disease. Lancet Neurol., 2013, 12(6), 597-608.
[http://dx.doi.org/10.1016/S1474-4422(13)70057-7]

Ganapa, S.V.; Ramani, M.D.; Ebunlomo, O.O.; Rahman, R.K.; Herschman, Y.; Mammis, A. Treatment of persistent hemiballism with deep brain stimulation of the globus pallidus internus: Case report and literature review. World Neurosurg., 2019, 132, 368-370.
[http://dx.doi.org/10.1016/j.wneu.2019.08.247]

Albanese, A.; Bhatia, K.; Bressman, S.B.; DeLong, M.R.; Fahn, S.; Fung, V.S.C.; Hallett, M.; Jankovic, J.; Jinnah, H.A.; Klein, C.; Lang, A.E.; Mink, J.W.; Teller, J.K. Phenomenology and classification of dystonia: A consensus update. Mov. Disord., 2013, 28(7), 863-873.
[http://dx.doi.org/10.1002/mds.25475]

Balint, B.; Mencacci, N.E.; Valente, E.M.; Pisani, A.; Rothwell, J.; Jankovic, J.; Vidailhet, M.; Bhatia, K.P. Author correction. Dystonia. Nat. Rev. Dis. Primers, 2018, 4(1), 37.
[http://dx.doi.org/10.1038/s41572-018-0039-y]

Jankovic, J. Botulinum toxin: State of the art. Mov. Disord., 2017, 32(8), 1131-1138.
[http://dx.doi.org/10.1002/mds.27072]

Termsarasab, P.; Thammongkolchai, T.; Frucht, S.J. Medical treatment of dystonia. J. Clin. Mov. Disord., 2016, 3, 19.
[http://dx.doi.org/10.1186/s40734-016-0047-6] [PMID: 28031858]

Cloud, L.J.; Jinnah, H.A. Treatment strategies for dystonia. Expert Opin. Pharmacother., 2010, 11(1), 5-15.
[http://dx.doi.org/10.1517/14656560903426171] [PMID: 20001425]

Reese, R.; Volkmann, J. Deep brain stimulation for the dystonias: Evidence, knowledge gaps, and practical considerations. Mov. Disord. Clin. Pract., 2017, 4(4), 486-494.
[http://dx.doi.org/10.1002/mdc3.12519]

American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders; American Psychiatric Association, 2013.

Johnson, K.A.; Worbe, Y.; Foote, K.D.; Butson, C.R.; Gunduz, A.; Okun, M.S. Tourette syndrome: Clinical features, pathophysiology, and treatment. Lancet Neurol., 2022, 4422(22), 1-12.

Martino, D.; Hedderly, T. Tics and stereotypies: A comparative clinical review. Parkinsonism Relat. Disord., 2019, 59, 117-124.
[http://dx.doi.org/10.1016/j.parkreldis.2019.02.005]

Martino, D.; Mink, J.W. Tic disorders. Continuum , 2013, 19(5), 1287-1311.
[http://dx.doi.org/10.1212/01.CON.0000436157.31662.af]

Cothros, N.; Medina, A.; Pringsheim, T. Current pharmacotherapy for tic disorders. Expert Opin. Pharmacother., 2020, 21(5), 567-580.
[http://dx.doi.org/10.1080/14656566.2020.1721465]

Pringsheim, T.; Okun, M.S.; Müller-Vahl, K.; Martino, D.; Jankovic, J.; Cavanna, A.E.; Woods, D.W.; Robinson, M.; Jarvie, E.; Roessner, V.; Oskoui, M.; Holler-Managan, Y.; Piacentini, J. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology, 2019, 92(19), 896-906.
[http://dx.doi.org/10.1212/WNL.0000000000007466]

Roessner, V.; Eichele, H.; Stern, J.S.; Skov, L.; Rizzo, R.; Debes, N.M.; Nagy, P.; Cavanna, A.E.; Termine, C.; Ganos, C.; Münchau, A.; Szejko, N.; Cath, D.; Müller-Vahl, K.R.; Verdellen, C.; Hartmann, A.; Rothenberger, A.; Hoekstra, P.J.; Plessen, K.J. European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: Pharmacological treatment. Eur. Child Adolesc. Psychiatry, 2022, 31(3), 425-441.
[http://dx.doi.org/10.1007/s00787-021-01899-z]

Mogwitz, S.; Buse, J.; Wolff, N.; Roessner, V. Update on the pharmacological treatment of tics with dopamine-modulating agents. ACS Chem. Neurosci., 2018, 9(4), 651-672.
[http://dx.doi.org/10.1021/acschemneuro.7b00460]

Behling, E.; Farhat, L.C.; Landeros-Weisenberger, A.; Bloch, M.H. META‐ANALYSIS: Efficacy and tolerability of vesicular monoamine transporter type 2 inhibitors in the treatment of tic disorders. Mov. Disord., 2022, 37(4), 684-693.
[http://dx.doi.org/10.1002/mds.28957]

Chen, J.J.; Ondo, W.G.; Dashtipour, K.; Swope, D.M. Tetrabenazine for the treatment of hyperkinetic movement disorders: A review of the literature. Clin. Ther., 2012, 34(7), 1487-1504.
[http://dx.doi.org/10.1016/j.clinthera.2012.06.010]

Billnitzer, A.; Jankovic, J. Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments. Neurotherapeutics. Springer Science and Business Media Deutschland GmbH, 2020, 17, 1681-1693.

Roessner, V.; Eichele, H.; Stern, J.S.; Skov, L.; Rizzo, R.; Debes, N.M. European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment.European Child and Adolescent Psychiatry. Springer Science and Business Media Deutschland GmbH, 2022, 31, 425-441.

Martinez-Ramirez, D.; Jimenez-Shahed, J.; Leckman, J.F.; Porta, M.; Servello, D.; Meng, F.G.; Kuhn, J.; Huys, D.; Baldermann, J.C.; Foltynie, T.; Hariz, M.I.; Joyce, E.M.; Zrinzo, L.; Kefalopoulou, Z.; Silburn, P.; Coyne, T.; Mogilner, A.Y.; Pourfar, M.H.; Khandhar, S.M.; Auyeung, M.; Ostrem, J.L.; Visser-Vandewalle, V.; Welter, M-L.; Mallet, L.; Karachi, C.; Houeto, J.L.; Klassen, B.T.; Ackermans, L.; Kaido, T.; Temel, Y.; Gross, R.E.; Walker, H.C.; Lozano, A.M.; Walter, B.L.; Mari, Z.; Anderson, W.S.; Changizi, B.K.; Moro, E.; Zauber, S.E.; Schrock, L.E.; Zhang, J-G.; Hu, W.; Rizer, K.; Monari, E.H.; Foote, K.D.; Malaty, I.A.; Deeb, W.; Gunduz, A.; Okun, M.S. Efficacy and safety of deep brain stimulation in tourette syndrome. The international tourette syndrome deep brain stimulation public database and registry. JAMA Neurol., 2018, 75(3), 353-359.
[http://dx.doi.org/10.1001/jamaneurol.2017.4317]

Baldermann, J.C.; Kuhn, J.; Schüller, T.; Kohl, S.; Andrade, P.; Schleyken, S.; Prinz-Langenohl, R.; Hellmich, M.; Barbe, M.T.; Timmermann, L.; Visser-Vandewalle, V.; Huys, D. Thalamic deep brain stimulation for tourette syndrome: A naturalistic trial with brief randomized, double-blinded sham-controlled periods. Brain Stimul., 2021, 14(5), 1059-1067.
[http://dx.doi.org/10.1016/j.brs.2021.07.003]

Factor, S.A. Management of tardive syndrome: Medications and surgical treatments. Neurotherapeutics, 2020, 17(4), 1694-1712.
[http://dx.doi.org/10.1007/s13311-020-00898-3]

Szota, A.M.; Scheel-Krüger, J. The role of glutamate receptors and their interactions with dopamine and other neurotransmitters in the development of tardive dyskinesia: Preclinical and clinical results. Behav. Pharmacol., 2020, 31(6), 511-523.
[http://dx.doi.org/10.1097/FBP.0000000000000563]

Zutshi, D.; Cloud, L.J.; Factor, S.A. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: Experience from a university-based movement disorder clinic. Tremor Other Hyperkinet. Mov. , 2014, 4, 266.
[http://dx.doi.org/10.5334/tohm.199]

Pinninti, N.R.; Faden, J.; Adityanjee, A. Are second-generation antipsychotics useful in tardive dystonia? Clin. Neuropharmacol., 2015, 38(5), 183-197.
[http://dx.doi.org/10.1097/WNF.0000000000000106]

Mulroy, E.; Balint, B.; Bhatia, K.P. Tardive syndromes. Pract. Neurol., 2020, 20(5), 368-376.
[http://dx.doi.org/10.1136/practneurol-2020-002566]

Bhidayasiri, R.; Jitkritsadakul, O.; Friedman, J.H.; Fahn, S. Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm. J. Neurol. Sci., 2018, 389, 67-75.
[http://dx.doi.org/10.1016/j.jns.2018.02.010]

Mentzel, T; van der Snoek, R; Lieverse, R; Oorschot, M; Viechtbauer, W; Bloemen, O Clozapine monotherapy as a treatment for antipsychotic-induced tardive dyskinesia: A meta-analysis. J. Clin. Psychiatry, , 2018, 79(6), 17r11852 .

Anderson, K.E.; Stamler, D.; Davis, M.D.; Factor, S.A.; Hauser, R.A.; Isojärvi, J.; Jarskog, L.F.; Jimenez-Shahed, J.; Kumar, R.; McEvoy, J.P.; Ochudlo, S.; Ondo, W.G.; Fernandez, H.H. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry, 2017, 4(8), 595-604.
[http://dx.doi.org/10.1016/S2215-0366(17)30236-5]

Fernandez, H.H.; Factor, S.A.; Hauser, R.A.; Jimenez-Shahed, J.; Ondo, W.G.; Jarskog, L.F.; Meltzer, H.Y.; Woods, S.W.; Bega, D.; LeDoux, M.S.; Shprecher, D.R.; Davis, C.; Davis, M.D.; Stamler, D.; Anderson, K.E. Randomized controlled trial of deutetrabenazine for tardive dyskinesia. Neurology, 2017, 88(21), 2003-2010.
[http://dx.doi.org/10.1212/WNL.0000000000003960]

Rascol, O.; Fabbri, M.; Poewe, W. Amantadine in the treatment of Parkinson’s disease and other movement disorders. Lancet Neurol., 2021, 20(12), 1048-1056.
[http://dx.doi.org/10.1016/S1474-4422(21)00249-0]

Pappa, S.; Tsouli, S.; Apostolou, G.; Mavreas, V.; Konitsiotis, S. Effects of amantadine on tardive dyskinesia. Clin. Neuropharmacol., 2010, 33(6), 271-275.
[http://dx.doi.org/10.1097/WNF.0b013e3181ffde32]

Lin, C-C.; Ondo, W.G. Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia. J. Neurol. Sci., 2018, 389, 48-54.
[http://dx.doi.org/10.1016/j.jns.2018.02.014]

Cornett, E.M.; Novitch, M.; Kaye, A.D.; Kata, V.; Kaye, A.M. Medication-induced tardive dyskinesia: A review and update. Ochsner J., 2017, 17(2), 162-174.
[PMID: 28638290]

Krause, P.; Kroneberg, D.; Gruber, D.; Koch, K.; Schneider, G.H.; Kühn, A.A. Long-term effects of pallidal deep brain stimulation in tardive dystonia: A follow-up of 5–14 years. J. Neurol., 2022, 269(7), 3563-3568.
[http://dx.doi.org/10.1007/s00415-022-10965-8]

Macerollo, A.; Deuschl, G. Deep brain stimulation for tardive syndromes: Systematic review and meta-analysis. J. Neurol. Sci., 2018, 389, 55-60.
[http://dx.doi.org/10.1016/j.jns.2018.02.013]

van den Heuvel, C.N.A.M.; Tijssen, M.A.J.; van de Warrenburg, B.P.C.; Delnooz, C.C.S. The symptomatic treatment of acquired dystonia: A systematic review. Mov. Disord. Clin. Pract., 2016, 3(6), 548-558.
[http://dx.doi.org/10.1002/mdc3.12400]

Gruber, D.; Südmeyer, M.; Deuschl, G.; Falk, D.; Krauss, J.K.; Mueller, J. Neurostimulation in tardive dystonia/dyskinesia: A delayed start, sham stimulation-controlled randomized trial. Brain Stimulation; Elsevier Inc., 2018, 11, 1368-1377.

Stahl, S.M. Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less “go” and more “stop” from the motor striatum for robust therapeutic effects. CNS Spectr., 2018, 23(1), 1-6.
[http://dx.doi.org/10.1017/S1092852917000621]

Claassen, D.O.; Carroll, B.; De Boer, L.M.; Wu, E.; Ayyagari, R.; Gandhi, S.; Stamler, D. Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease. J. Clin. Mov. Disord., 2017, 4(1), 3.
[http://dx.doi.org/10.1186/s40734-017-0051-5]

Mehanna, R.; Hunter, C.; Davidson, A.; Jimenez-Shahed, J.; Jankovic, J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov. Disord., 2013, 28(2), 210-215.
[http://dx.doi.org/10.1002/mds.25278]

Prestwick Pharmaceuticals, Inc. 2008. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf (cited: 7th of November 2022)

Teva Pharmaceuticals, USA, Inc. 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209885lbl.pdf (cited: 7th of November 2022).

Neurocrine Biosciences, Inc. 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209241lbl.pdf (cited: 7th of November 2022).

Jankovic, J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin. Pharmacother., 2016, 17(18), 2461-2470.
[http://dx.doi.org/10.1080/14656566.2016.1258063]

Kaur, N.; Kumar, P.; Jamwal, S.; Deshmukh, R.; Gauttam, V. Tetrabenazine: Spotlight on drug review. Ann. Neurosci., 2016, 23(3), 176-185.

Wisidagama, S.; Selladurai, A.; Wu, P.; Isetta, M.; Serra-Mestres, J. Recognition and management of antipsychotic-induced parkinsonism in older adults: A narrative review. Medicines , 2021, 8(6), 24.
[http://dx.doi.org/10.3390/medicines8060024]

Blanchet, K. Drug-induced parkinsonism: diagnosis and management. J. Parkinson. Restl. Leg. Syndr., 2016 2016. Available from: www.dovepress.com

Bashir, H.; Jankovic, J. Treatment options for chorea.Exp. Rev. Neurotherap; Taylor and Francis Ltd, 2018, 18, 51-63.
[http://dx.doi.org/10.1080/14737175.2018.1403899]

Preskorn, S.H.; Fahnestock, P.A.; Carpenter, D.; Ross, R.; Docherty, J.P.; Alexopoulos, S. The roadmap for antipsychotic psychopharmacology: An overview. J. Clin. Psychiatry, 2007, 68.

Gardner, D.M.; Baldessarini, R.J.; Waraich, P. Modern antipsychotic drugs: A critical overview. Canad. Med. Assoc. J., 2005, 172, 1703-1711.

Waln, O.; Jankovic, J.; Cambridge, H.; Arnold, W.; Wilkins, W.B. An update on tardive dyskinesia: From phenomenology to treatment. Tremor Other Hyperkinet. Mov., 2013, 3, 03.
[http://dx.doi.org/10.5334/tohm.165]

Aguilar-Henriquez, A.; Mbbs, T.T.; Andrés, A.H.; Luba, L.; James, M. Psychotropic idiosyncratic drug reactions: A brief review of proposed mechanisms; In:; Int. J. Psychiatr. Res, 2019, p. 2.

Strawn, J.R.; Keck, P.E.; Caroff, S.N. Treatment in psychiatry neuroleptic malignant syndrome scope and nature of neuroleptic malignant syndrome. Am. J. Psychiatry, 2007, 164.

Jankovic, J. Medical treatment of dystonia. Mov. Disord., 2013, 28(7), 1001-1012.
[http://dx.doi.org/10.1002/mds.25552]

Wong, J.; Delva, N. Clozapine-induced seizures: Recognition and treatment. Can. J. Psychiatry, 2007, 52(7), 457-463.
[http://dx.doi.org/10.1177/070674370705200708]

Osborne, I.J.; McIvor, R.J. Clozapine-induced myoclonus: A case report and review of the literature. Ther. Adv. Psychopharmacol., 2015, 5(6), 351-356.
[http://dx.doi.org/10.1177/2045125315612015]

Hampe, C.S.; Mitoma, H.; Manto, M. GABA and Glutamate: Their transmitter role in the CNS and pancreatic islets.In: GABA And Glutamate - New Developments In Neurotransmission Research; InTech, , 2018.

Excitatory, H.; John, M.S.; Adron, H.R. GABA and the GABAa receptor. J. Neurochem., 1997, 21, 1-27-131.

Soyka, M. Treatment of benzodiazepine dependence. N. Engl. J. Med., 2017, 376(12), 1147-1157.
[http://dx.doi.org/10.1056/NEJMra1611832]

de las Cuevas, C.; Sanz, E.; de la Fuente, J. Benzodiazepines: More “behavioural” addiction than dependence. Psychopharmacology , 2003, 167(3), 297-303.
[http://dx.doi.org/10.1007/s00213-002-1376-8]

Gracies, J.M.; Nance, P.; Elovic, E.; McGuire, J.; Simpson, D.M. Traditional pharmacological treatments for spasticity part II: General and regional treatments. Muscle Nerve, 1997, 20(S6), 92-120.
[http://dx.doi.org/10.1002/(SICI)1097-4598(1997)6+<92:AID-MUS7>3.0.CO;2-E]

Jinnah, H.A.; Factor, S.A. Diagnosis and treatment of dystonia. Neurol. Clin., 2015, 33(1), 77-100.
[http://dx.doi.org/10.1016/j.ncl.2014.09.002]

Holm, K.J.; Goa, K.L.; Cluydts, R. Zolpidem: An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs, 2000, 59(4), 865-889.

Huang, M.C.; Lin, H.Y.; Chen, C.H. Dependence on zolpidem. Psychiatry Clin. Neurosci., 2007, 61(2), 207-208.
[http://dx.doi.org/10.1111/j.1440-1819.2007.01644.x]

Romito, J.W.; Turner, E.R.; Rosener, J.A.; Coldiron, L.; Udipi, A.; Nohrn, L.; Tausiani, J.; Romito, B.T. Baclofen therapeutics, toxicity, and withdrawal: A narrative review. SAGE Open Med., 2021, 9.
[http://dx.doi.org/10.1177/20503121211022197]

Caulfield, MP. Birdsall, NJM International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev., 1998, 50(2), 279-290.

Kruse, A.C.; Kobilka, B.K.; Gautam, D.; Sexton, P.M.; Christopoulos, A.; Wess, J. Muscarinic acetylcholine receptors: Novel opportunities for drug development. Nat. Rev. Drug Discov. Nature Publishing Group, 2014, 13, 549-560.

Miller, C.A. Anticholinergics: The good and the bad. Geriatr. Nurs., 2002, 23(5), 286-287.
[http://dx.doi.org/10.1067/mgn.2002.128791]

Downs, A.M.; Fan, X.; Donsante, C.; Jinnah, H.A.; Hess, E.J. Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia. Neurobiol. Dis., 2019, 125, 115-122.
[http://dx.doi.org/10.1016/j.nbd.2019.01.012]

Galarraga, E.; Herná Ndez-Ló Pez, S.; Reyes, A.; Miranda, I.; Bermudez-Rattoni, F.; Vilchis, C. Cholinergic modulation of neostriatal output: A functional antagonism between different types of muscarinic receptors. J. Neurosci., 1999, 19(9), 3629-3638.
[http://dx.doi.org/10.1523/JNEUROSCI.19-09-03629.1999]

Bergman, H.; Soares-Weiser, K. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst. Rev., 2018, 1(1), CD000204.
[http://dx.doi.org/10.1002/14651858.CD000204.pub2]

Artukoglu, B.B.; Li, F.; Szejko, N.; Bloch, M.H. Pharmacologic treatment of tardive dyskinesia: A meta-analysis and systematic review. J. Clin. Psychiatry., 2020, 81(4), 19r12798.
[http://dx.doi.org/10.4088/JCP.19r12798]

Stroup, T.S.; Gray, N. Management of common adverse effects of antipsychotic medications. World Psychiatry, 2018, 17(3), 341-356.
[http://dx.doi.org/10.1002/wps.20567]

López-Álvarez, J.; Sevilla-Llewellyn-Jones, J.; Agüera-Ortiz, L. Anticholinergic drugs in geriatric psychopharmacology. Front. Neurosci., 2019, 13, 1309.

Zhou, Y.; Danbolt, N.C. Glutamate as a neurotransmitter in the healthy brain. J. Neural Transm., 2014, 121(8), 799-817.
[http://dx.doi.org/10.1007/s00702-014-1180-8]

Sanacora, G.; Zarate, C.A.; Krystal, J.H.; Manji, H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov., 2008, 7(5), 426-437.
[http://dx.doi.org/10.1038/nrd2462]

Meldrum, BS. Glutamate and glutamine in the brain glutamate as a neurotransmitter in the brain: Review of physiology and pathology. J. Nutr., 2000, 130(4S), 1007S-1015S.

Rascol, O.; Fabbri, M.; Poewe, W. Amantadine in the treatment of Parkinson’s disease and other movement disorders.The Lancet Neurology; Elsevier, 2021, 20, 1048-1056.

Dragašević-Mišković, N.; Petrović, I.; Stanković, I.; Kostić, V.S. Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients. Expert Opinion on Pharmacotherapy; Taylor and Francis Ltd,, 2019, 20, 219-230.

Caroff, S.N.; Jr, MJ.F. Revisiting amantadine as a treatment for drug-induced movement disorders. Ann. Clin. Psychiatry, 2020, 32(3), 198-208.

Kubo, S.; Iwatake, A.; Ebihara, N.; Murakami, A.; Hattori, N. Visual impairment in Parkinson’s disease treated with amantadine: Case report and review of the literature. Parkinsonism Relat. Disord., 2008, 14(2), 166-169.
[http://dx.doi.org/10.1016/j.parkreldis.2007.03.003]

Chang, C.; Ramphul, K. In: StatPearls; StatPearls Publishing, 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499953/ (cited: 14th November 2022).

Siniscalchi, A.; Gallelli, L.; De Sarro, G. Use of antiepileptic drugs for hyperkinetic movement disorders. Curr. Neuropharmacol., 2010, 8(4), 359-366.
[http://dx.doi.org/10.2174/157015910793358187]

Bialer, M.; White, H.S. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov., 2010, 9(1), 68-82.
[http://dx.doi.org/10.1038/nrd2997]

Yu, L.; Yan, J.; Wen, F.; Wang, F.; Liu, J.; Cui, Y.; Li, Y. Revisiting the efficacy and tolerability of topiramate for tic disorders: A meta-analysis. J. Child Adolesc. Psychopharmacol., 2020, 30(5), 316-325.
[http://dx.doi.org/10.1089/cap.2019.0161]

Walia, K.S.; Khan, E.A.; Ko, D.H.; Raza, S.S.; Khan, Y.N. Side effects of antiepileptics: A review. Pain Pract., 2004, 4(3), 194-203.
[http://dx.doi.org/10.1111/j.1533-2500.2004.04304.x]

Mutanana, N.; Tsvere, M.; Chiweshe, M.K. General side effects and challenges associated with anti-epilepsy medication: A review of related literature. Afr. J. Prim. Health Care Fam. Med., 2020, 12(1), e1-e5.
[http://dx.doi.org/10.4102/phcfm.v12i1.2162]

Arnon, S.S.; Schechter, R.; Inglesby, T.V.; Henderson, D.A.; Bartlett, J.G.; Ascher, M.S. Botulinum toxin as a biological weapon medical and public health management. JAMA, 2001, 285(8), 1059-1070.

Dressler, D.; Adib Saberi, F. Botulinum toxin: Mechanisms of action. Eur. Neurol., 2005, 53(1), 3-9.
[http://dx.doi.org/10.1159/000083259]

Marsh, W.A.; Monroe, D.M.; Brin, M.F.; Gallagher, C.J. Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. BMC Neurol., 2014, 14(1), 91.
[http://dx.doi.org/10.1186/1471-2377-14-91]

Anandan, C.; Jankovic, J. Botulinum toxin in movement disorders: An update. Toxins , 2021, 13(1), 42.
[http://dx.doi.org/10.3390/toxins13010042]

Kassir, M.; Gupta, M.; Galadari, H.; Kroumpouzos, G.; Katsambas, A.; Lotti, T. Complications of botulinum toxin and fillers: A narrative review. J. Cosmet. Dermatol., 2020, 19(3), 570-573.
[http://dx.doi.org/10.1111/jocd.13266]

Kroumpouzos, G.; Kassir, M.; Gupta, M.; Patil, A.; Goldust, M. Complications of Botulinum toxin A: An update review. J. Cosmet. Dermatol., 2021, 20, 1585-15920.

Witmanowski, H.; Błochowiak, K. The whole truth about botulinum toxin: A review. Postepy Dermatologii i Alergologii. Termedia Publishing House Ltd, 2021, 37, 853-861.

Jinnah, H.A. Medical and surgical treatments for dystonia. Neurol. Clin., 2020, 38(2), 325-348.
[http://dx.doi.org/10.1016/j.ncl.2020.01.003]

George, E.; Shneyder, N. Reduction in post-botulinum toxin flu-like symptoms after injection with incobotulinum toxin. Neurology, 2014, 2014(08), 82.

Baizabal-Carvallo, J.F.; Jankovic, J.; Pappert, E. Flu-like symptoms following botulinum toxin therapy. Toxicon, 2011, 58(1), 1-7.
[http://dx.doi.org/10.1016/j.toxicon.2011.04.019]

Albrecht, P.; Jansen, A.; Lee, J.I.; Moll, M.; Ringelstein, M.; Rosenthal, D.; Bigalke, H.; Aktas, O.; Hartung, H-P.; Hefter, H. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology, 2019, 92(1), e48-e54.
[http://dx.doi.org/10.1212/WNL.0000000000006688]

Ho, W.W.S.; Albrecht, P.; Calderon, P.E.; Corduff, N.; Loh, D.; Martin, M.U.; Park, J-Y.; Suseno, L.S.; Tseng, F-W.; Vachiramon, V.; Wanitphakdeedecha, R.; Won, C-H.; Yu, J.N.T.; Dingley, M. Emerging trends in botulinum neurotoxin a resistance: An international multidisciplinary review and consensus. Plast. Reconstr. Surg. Glob. Open, 2022, 10(6), e4407.
[http://dx.doi.org/10.1097/GOX.0000000000004407]

Farr, S.T. Resistance to botulinum toxins in aesthetics. Botulinum Toxins and Botulism; Nova Science Publishers, Inc., 2015, pp. 1-15.

Ashkan, K.; Rogers, P.; Bergman, H.; Ughratdar, I. Insights into the mechanisms of deep brain stimulation. Nat. Rev. Neurol. Nature Publishing Group, 2017, 13, 548-554.

Chan, D.T.M.; Zhu, X.L.; Yeung, J.H.M.; Mok, V.C.T.; Wong, E.; Lau, C. Complications of deep brain stimulation: A collective review. Asian J. Surgery. Elsevier. Pte Ltd: Singapore, 2009, 32, 258-263.

Patel, D.M.; Walker, H.C.; Brooks, R.; Omar, N.; Ditty, B.; Guthrie, B.L. Adverse events associated with deep brain stimulation for movement disorders: Analysis of 510 consecutive cases. Oper. Neurosurg. , 2015, 11(1), 190-199.
[http://dx.doi.org/10.1227/NEU.0000000000000659]

Jung, I.H.; Chang, K.W.; Park, S.H.; Chang, W.S.; Jung, H.H.; Chang, J.W. Complications after deep brain stimulation: A 21-year experience in 426 patients. Front. Aging Neurosci., 2022, 14, 819730.
[http://dx.doi.org/10.3389/fnagi.2022.819730]

Zarzycki, M.Z.; Domitrz, I. Stimulation-induced side effects after deep brain stimulation: A systematic review. Acta Neuropsychiatrica; Cambridge University Press,; , 2020, 32, pp. 57-64.

Strotzer, Q.D.; Kohl, Z.; Anthofer, J.M.; Faltermeier, R.; Schmidt, N.O.; Torka, E.; Greenlee, M.W.; Fellner, C.; Schlaier, J.R.; Beer, A.L. Structural connectivity patterns of side effects induced by subthalamic deep brain stimulation for Parkinson’s disease. Brain Connect., 2022, 12(4), 374-384.
[http://dx.doi.org/10.1089/brain.2021.0051]

Reese, R.; Volkmann, J. Deep brain stimulation for the dystonias: Evidence, knowledge gaps, and practical considerations. Movement Disorders Clinical Practice; Wiley-Blackwell, 2017, 4, 486-494.

Zarzycki, M.Z.; Domitrz, I. Stimulation-induced side effects after deep brain stimulation: A systematic review. . Acta Neuropsychiatrica; Cambridge University Press, ; , 2020, 32, pp. 57-64.

Au, K.L.K.; Wong, J.K.; Tsuboi, T.; Eisinger, R.S.; Moore, K.; Lemos Melo Lobo Jofili Lopes, J.; Holland, M.T.; Holanda, V.M.; Peng-Chen, Z.; Patterson, A.; Foote, K.D.; Ramirez-Zamora, A.; Okun, M.S.; Almeida, L. Globus pallidus internus (GPi) deep brain stimulation for Parkinson’s disease: Expert review and commentary. Neurol. Ther., 2021, 10(1), 7-30.
[http://dx.doi.org/10.1007/s40120-020-00220-5]

Buhmann, C.; Huckhagel, T.; Engel, K.; Gulberti, A.; Hidding, U.; Poetter-Nerger, M.; Goerendt, I.; Ludewig, P.; Braass, H.; Choe, C.; Krajewski, K.; Oehlwein, C.; Mittmann, K.; Engel, A.K.; Gerloff, C.; Westphal, M.; Köppen, J.A.; Moll, C.K.E.; Hamel, W. Adverse events in deep brain stimulation: A retrospective long-term analysis of neurological, psychiatric and other occurrences. PLoS One, 2017, 12(7), e0178984.
[http://dx.doi.org/10.1371/journal.pone.0178984]

An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia (AUDYT). 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT04173260 (Cited: 21st December 2022).

Bledsoe, I.O.; Viser, A.C.; San Luciano, M. Treatment of dystonia: Medications, neurotoxins, neuromodulation, and rehabilitation. Neurotherapeutics, 2020, 17(4), 1622-1644.
[http://dx.doi.org/10.1007/s13311-020-00944-0]

Solish, N.; Carruthers, J.; Kaufman, J.; Rubio, R.G.; Gross, T.M.; Gallagher, C.J. Overview of daxibotulinumtoxina for injection: A novel formulation of botulinum toxin type A. Drugs, 2021, 81(18), 2091-2101.
[http://dx.doi.org/10.1007/s40265-021-01631-w]

Berweck, S.; Feldkamp, A.; Francke, A.; Nehles, J.; Schwerin, A.; Heinen, F. Sonography-guided injection of botulinum toxin a in children with cerebral palsy. Neuropediatrics, 2002, 33(4), 221-223.
[http://dx.doi.org/10.1055/s-2002-34500]

Chen, HWW. Ultrasound-guided botulinum toxin injections and EMG biofeedback therapy the lower limb muscle spasm after cerebral infarction. Eur. Rev. Med. Pharmacol. Sci., 2015, 19(9), 1696-1699.

Sung, D.H.; Choi, J.Y.; Kim, D.H.; Kim, E.S.; Son, Y.I.; Cho, Y.S.; Lee, S.J.; Lee, K-H.; Kim, B-T. Localization of dystonic muscles with 18F-FDG PET/CT in idiopathic cervical dystonia. J. Nucl. Med., 2007, 48(11), 1790-1795.
[http://dx.doi.org/10.2967/jnumed.107.044024]

Krauss, J.K.; Lipsman, N.; Aziz, T.; Boutet, A.; Brown, P.; Chang, J.W. Technology of deep brain stimulation: Current status and future directions. Nat. Rev. Neurol., 2021, 17, 75-87.

Horisawa, S.; Yamaguchi, T.; Abe, K.; Hori, H.; Sumi, M.; Konishi, Y.; Taira, T. A single case of MRI-guided focused ultrasound ventro-oral thalamotomy for musician’s dystonia. J. Neurosurg., 2019, 131(2), 384-386.
[http://dx.doi.org/10.3171/2018.5.JNS173125]

Fasano, A.; Llinas, M.; Munhoz, R.P.; Hlasny, E.; Walter Kucharczyk, M. Lozano, AM MRI-guided focused ultrasound thalamotomy in non-ET tremor syndromes. Neurology, 2017, 89(8), 771-775.
[http://dx.doi.org/10.1212/WNL.0000000000004268]